Human T-cell response to myelin basic protein peptide (83-99): Extensive heterogeneity in antigen recognition, function, and phenotype

Neurology

Volumn 49, Issue 4, 1997, Pages 1116-1126

  Hemmer, B ^a   Vergelli, M ^a   Tranquill, L ^a   Conlon, P ^c   Ling, N ^c   McFarland, H F ^a   Martin, R ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NEUROCRINE BIOSCIENCES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYELIN BASIC PROTEIN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; ETIOLOGY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0030701864     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.4.1116     Document Type: Article

References (56)

1. Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10: 153-187.
2. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579-621.
3. Chou YK, Vainiene M, Whitham R, et al. Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA-class II restriction molecules. J Neurol Sci 1989;23:207-216.
4. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
5. Pette, M, Fujita K, Wilkinson D, et al. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple sclerosis patients and healthy donors. Proc Natl Acad Sci USA 1990;87:7968-7972.
6. Martin R, Utz U, Coligan JE, et al. Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol 1992;148:1359-1366.
7. Ando DG, Clayton J, Kono D, Urban JL, Sercarz EE. Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell Immunol 1989;124:132-143.
8. Kojima K, Berger T, Lassmann H, et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100β molecule, a calcium binding protein of astroglia. J Exp Med 1994;180:817-829.
9. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature 1992;356:63-66.
10. Fritz RB, Skeen MJ, Jen-Chou CH, Garda M, Egorov IK. Major histocompatibility complex-linked control of the murine immune response to myelin basic protein. J Immunol 1985; 134:2328-2332.
11. Martin R, McFarland HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995;32:121-182.
12. Acha-Orbae H, Mitchell L, Timmermann L, et al. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell 1988;54:263-273.
13. Urban JL, Kumar V, Kono DH, et al. Restricted use of the T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. Cell 1988;54:577-592.
14. Zamvil SS, Mitchell DJ, Lee NE, et al. Predominant expression of a T cell receptor Vβ gene subfamily in autoimmune encephalomyelitis. J Exp Med 1988;167:1586-1596.
15. Burns FR, Li X, Shen N, et al. Both rat and mouse T cell receptors specific for the encephalitogenic determinant of myelin basic protein use similar Vα and Vβ chain genes even though the major histocompatibility complex and encephalitogenic determinants being recognized are different. J Exp Med 1989;169:27-39.
16. Chluba J, Steeg C, Becker A, Wekerle H, Epplen JT. T cell receptor β chain usage in myelin basic protein-specific rat T lymphocytes. Eur J Immunol 1989;19:279-284.
17. Urban JL, Horvath SJ, Hood L. Autoimmune T cells: immune recognition of normal and variant peptide epitopes and peptide-based therapy. Cell 1989;59:257-271.
18. Wraith DC, Smilek DE, Mitchell DJ, Steinman L, McDevitt HO. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell 1989;59:247-255.
19. Sakai K, Zamvil SS, Mitchell DJ, Hodgkinson S, Rothbard JB, Steinman L. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins. Proc Natl Acad Sei USA 1989;86:9470-9474.
20. Aharoni R, Teitelbaum D, Arnon R, Puri J. Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen-Ia complex. Nature 1991;351:147-150.
21. Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide against experimental autoimmune encephalomyelitis. Nature 1989;341:541-544.
22. Howell MD, Winters ST, Olee T, Powell HC, Carlo DJ, Brostoff SW. Vaccination against experimental allergic autoimmune encephalomyelitis with T cell receptor peptides. Science 1989;246:668-670.
23. Higgins PJ, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J Immunol 1988;140:440-445.
24. Chen Y, Kuchroo VK, Inobe J-I, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 1994;265:1237-1240.
25. Critchfield JM, Racke MK, Züñiga-Pflücker JC, Cannella B, Raine CS, Goverman J, Lenardo MJ. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 1994;263:1139-1143.
26. Kuchroo VK, Greer JM, Kaul D, et al. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 1994;153: 3326-3336.
27. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon γ and tumor necrosis factor a production. J Exp Med 1994;180:2227-2237.
28. Nicholson LB, Greer JM, Sobel RA, Lees MB, Kuchroo VK. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995;3:397-405.
29. Brocke S, Gijbels K, Allegretta M, et al. Dynamics of autoimmune T cell infiltration: reversal of paralysis and disappearance of inflammation following treatment of experimental encephalomyelitis with a myelin basic protein peptide analog. Nature 1996;379:343-346.
30. Martin R, Howell MD, Jaraquemada D, et al. A myelin basic protein peptide is recognized by cytotoxic T cells in the context of four HLA-DR types associated with multiple sclerosis. J Exp Med 1991;173:19-24.
31. Deibler GE, Martenson RE, Kies MW. Large scale preparation of myelin basic protein from central nervous system tissue of several mammalian species. Prep Biochem 1972;2:139-165.
32. Ling N, Esch F, Böhlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci USA 1984;81:4302-4306.
33. Jaraquemada D, Martin R, Rosen-Bronson S, Flerlage M, McFarland HF, Long EO. HLA-DR2a is the dominant restriction molecule for the cytotoxic T cell response to myelin basic protein in DR2Dw2 individuals. J Immunol 1990;145:2880-2885.
34. Utz U, Biddison WE, McFarland HF, McFarlin DE, Flerlage M, Martin R. Skewed T cell receptor repertoire in genetically identical twins with multiple sclerosis correlates with disease. Nature 1993;364:243-247.
35. Vogt AB, Kropshofer H, Kalbacher H, et al. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol 1994;153:1665-1673.
36. Wucherpfennig KW, Sette A, Southwood S, Oseroff C, Matsui M, Strominger JL, Hafler DA. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med 1994;179:279-290.
37. Hemmer B, Vergelli M, Calabresi P, Huang T, McFarland HF, Martin R. Cytokine phenotype of human autoreactive T cell clones specific for the immunodominant myelin basic protein peptide (83-99). J Neurosci Res 1996;45:852-862.
38. Richert JR, Robinson ED, Deibler GE, Martenson RE, Dragovic LJ, Kies MW. Human cytotoxic T-cell recognition of a synthetic peptide of myelin basic protein. Ann Neurol 1989; 26:342-346.
39. Vergelli M, Hemmer B, Muraro PA, et al. Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis. J Immunol 1997;158:2756-2761.
40. Del Prete G, De Carli M, Almerigogna F, et al. Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines. FASEB J 1995;9:81-86.
41. Martin R, Jaraquemada D, Flerlage MJ, et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol 1990;145:540-548.
42. Acha-Orbea H, Steinman L, McDevitt HO. T cell receptors in murine autoimmune diseases. Annu Rev Immunol 1989;7: 371-406.
43. Hafler DA, Saadeh MG, Kuchroo VK, Milford E, Steinman L. TCR usage in human and experimental demyelinating disease. Immunol Today 1996;17:152-159.
44. S molecules. J Immunol 1990;145:1687-1693.
45. Ishioka GY, Adorini A, Guery J-C, et al. Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. J Immunol 1994;152:4310-4319.
46. Evavold BD, Sloan-Lancaster J, Allen PM. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol Today 1993;14:602-609.
47. Sette A, Alexander J, Rupert J, et al. Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol 1994;12:413-431.
48. Jameson SC, Bevan MJ. T cell receptor antagonists and partial agonists. Immunity 1995;2:1-11.
49. Levine S, Hoenig EM, Kies MW. Allergic encephalomyelitis: passive transfer prevented by encephalitogen. Science 1968; 161:1155-1157.
50. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 1996;184:19-29.
51. Vergelli M, Hemmer B, Utz U, et al. Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99). Eur J Immunol 1996;26:2624-2634.
52. Vergelli M, Hemmer B, Kalbus M, et al. Modifications of peptide ligands enhancing T cell responsiveness imply large numbers of stimulatory ligands. J Immunol 1997;158:3746-3752.
53. Hemmer B, Fleckenstein B, Vergelli M, Jung G, McFarland HF, Martin R, Wiesmüller K-H. Identification of high potency microbial and self ligands for a human autoreactive class II restricted T cell clone. J Exp Med 1997;45:1651-1659.
54. Windhagen A, Scholz C, Höllsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995;2:373-380.
55. Genain CPA, Abel K, Belmar N, et al. Late complications of immune deviation therapy in a nonhuman primate. Science 1996;274:2054-2057.
56. Singer GG, Abbas AK. The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity 1996;5:365-371.